Advantages and disadvantages of biodegradable platforms in drug eluting stents

Table 1 Comparison between published trials of biodegradable eluting stents

Name	Polymer	Stent design	Drug	Drug per stent length (μg/mm2)	Polymer degradation	Drug release
ISAR-TEST-3[35]	PLA	316L stainless steel microporus stent	Sirolimus	4.8	6-9 wk	28 d (95%)
ISAR TEST-4[36]	PLA	316L stainless-steel microporus stent	Sirolimus	4.8	6-9 wk	28 d (95%)
NOBORI 1[34]	PLA	Stainless-steel S-stent	Biolimus	15.6	9-12 mo	Two phases: immediately after stent implantation; sustained drug release over 9-12 mo
NOBORI CORE[33]	PLA	Stainless-steel S-stent	Biolimus	15.6	9-12 mo	Two phases: immediately after stent implantation; sustained drug release over 9-12 mo
LEADERS[28]	PLA	Flexible stainless- steel stent	Biolimus	15.6	6-9 mo	6-9 mo
PAINT[38]	PLA+	316L stainless metallic platform	Paclitaxel and Sirolimus	6.4 (PES)	7 mo	9-11 d (50%)
	PLGA			6.6 (SES)		38 d (90%)
						48 d (100%)
EUCATAX[39]	PLGA	Stainless steel open cell with glycocalix layer	Paclitaxel	11 to 43	6-8 wk	6-8 wk

PLA: Polylactic acid; PLGA: Polylactic-co-glycolic acid; PES: Paclitaxel-eluting stent; SES: Sirolimus-eluting stent; ISAR: Individualized Drug Eluting Stent System to Abrogate Restenosis; LEADERS: Limus Eluted from a Durable vs Erodable Stent Coating.